These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9607574)

  • 21. Implications of the structure of human uridine phosphorylase 1 on the development of novel inhibitors for improving the therapeutic window of fluoropyrimidine chemotherapy.
    Roosild TP; Castronovo S; Fabbiani M; Pizzorno G
    BMC Struct Biol; 2009 Mar; 9():14. PubMed ID: 19291308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy.
    Al Safarjalani ON; Zhou XJ; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):145-50. PubMed ID: 11565561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase.
    Niedzwicki JG; Chu SH; el Kouni MH; Rowe EC; Cha S
    Biochem Pharmacol; 1982 May; 31(10):1857-61. PubMed ID: 7104017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10.
    Ashour OM; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
    Biochem Pharmacol; 2000 Sep; 60(5):687-92. PubMed ID: 10927027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
    Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
    Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine.
    Ashour OM; Naguib FN; Panzica RP; Al Safarjalani ON; el Kouni MH
    Biochem Pharmacol; 2000 Aug; 60(3):427-31. PubMed ID: 10856438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.
    Peters GJ; van Groeningen CJ; Laurensse EJ; Lankelma J; Leyva A; Pinedo HM
    Cancer Chemother Pharmacol; 1987; 20(2):101-8. PubMed ID: 3664929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.
    Cao D; Russell RL; Zhang D; Leffert JJ; Pizzorno G
    Cancer Res; 2002 Apr; 62(8):2313-7. PubMed ID: 11956089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
    Ho DH; Covington W; Brown N; Lin SN; Pazdur R; Huo YY; Creaven PJ; Rustum YM; Meropol NJ; Lassere Y; Kuritani J; Hayakawa T
    Cancer Chemother Pharmacol; 2000; 46(5):351-6. PubMed ID: 11127938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake.
    Darnowski JW; Handschumacher RE
    Cancer Res; 1986 Jul; 46(7):3490-4. PubMed ID: 3708581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-activity relationship of nucleobase ligands of uridine phosphorylase from Toxoplasma gondii.
    Iltzsch MH; Klenk EE
    Biochem Pharmacol; 1993 Nov; 46(10):1849-58. PubMed ID: 8250971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiation of 5-fluoro-2'-deoxyuridine antineoplastic activity by the uridine phosphorylase inhibitors benzylacyclouridine and benzyloxybenzylacyclouridine.
    Chu MY; Naguib FN; Iltzsch MH; el Kouni MH; Chu SH; Cha S; Calabresi P
    Cancer Res; 1984 May; 44(5):1852-6. PubMed ID: 6231986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
    Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
    Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
    Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
    Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.